Irritable bowel syndrome is not uncommon, and depending on who you talk to, it’s either under or over-diagnosed – because it’s a poorly understood condition. However you look at it though, it’s good to know what treatments are out there.
This double blinded placebo controlled trial in NEJM looked at rifaximin (often used for traveller’s diarrhoea), an antibiotic which has the unique property of not crossing through the gastrointestinal wall – which makes it useful for taking out gut flora.
Looking at the results, there was about a 10% difference between the two groups, in favour of rifaximin.
Interesting stuff – check it out in NEJM over here.